FDA Approves Effient to Reduce the Risk of Heart Attack in Angioplasty Patients
The U.S. Food and Drug Administration has approved the blood-thinning drug Effient tablets (prasugrel) to reduce the risk of blood clots from forming in patients who undergo angioplasty, a common procedure to unblock a clogged coronary artery.